Orchard Therapeutics Overview

  • Founded
  • 2015
Founded
  • Status
  • Public
  • Employees
  • 234
Employees
  • Stock Symbol
  • ORTX
Stock Symbol
  • Investments
  • 1
  • Share Price
  • $6.08
  • (As of Monday Closing)

Orchard Therapeutics General Information

Description

Orchard Therapeutics PLC is a United Kingdom-based commercial-stage, a fully-integrated biopharmaceutical company. The company is engaged in transforming the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. It operates in three geographic regions: the United Kingdom, European Union, and the United States. Orchard Rx is focusing on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, used for the treatment of ADA-SCID five lentiviral product candidates.

Contact Information

Formerly Known As
Newincco 1387
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 108 Cannon Street
  • London EC4N 6EU
  • England, United Kingdom
+44 020 0000 0000

Orchard Therapeutics Timeline

2018201920202021
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Orchard Therapeutics Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$6.08 $5.96 $3.76 - $12.09 $733M 121M 1.39M -$1.53

Orchard Therapeutics Financials Summary

In Thousands,
USD
TTM 31-Dec-2020 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 279,063 279,063 985,570 1,273,300
Revenue 2,595 2,595 2,513 2,076
EBITDA (151,563) (151,563) (169,811) (228,326)
Net Income (151,979) (151,979) (163,422) (230,495)
Total Assets 280,937 280,937 399,281 366,042
Total Debt 58,167 58,167 45,911 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Orchard Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Orchard Therapeutics‘s full profile, request access.

Request a free trial

Orchard Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Orchard Therapeutics‘s full profile, request access.

Request a free trial

Orchard Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Orchard Therapeutics PLC is a United Kingdom-based commercial-stage, a fully-integrated biopharmaceutical company. The c
Drug Discovery
London, United Kingdom
234 As of 2021
00000
000000000 00000

00000000

n voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non
0000000000000
Gaithersburg, MD
00 As of 0000
00000
0000 0000-00-00
00000000 00000

000000 0

velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, s
0000000000000
Plymouth Meeting, PA
000 As of 0000
000.00
00000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Orchard Therapeutics Competitors (70)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NexImmune Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
000000 00000000000 Corporation Plymouth Meeting, PA 000 000.00 00000000 000.00
0000000000 Venture Capital-Backed Abingdon, United Kingdom 000 00.000 00000000 00.000
00000000 Formerly VC-backed Paris, France 00 000.00 000000000 000.00
000000 00000000000 Corporation Cambridge, MA 000 00000 000000 - 000 00000
You’re viewing 5 of 70 competitors. Get the full list »

Orchard Therapeutics Executive Team (13)

Name Title Board Seat Contact Info
Hubert Gaspar Chief Executive Officer & Board Member
Frank Thomas Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
John Cerio Chief Human Resources Officer
John Ilett Chief Legal Officer, Chief of Staff & Company Secretary
Nicolas Koebel Chief of Staff & Head of Program Management
You’re viewing 5 of 13 executive team members. Get the full list »

Orchard Therapeutics Board Members (19)

Name Representing Role Since
Alexander Pasteur Ph.D F-Prime Capital Board Member 000 0000
Alicia Secor Self Board Member 000 0000
Charles Rowland Jr. Self Board Member 000 0000
Helen Wise Orchard Therapeutics Board Member 000 0000
Hubert Gaspar Orchard Therapeutics Chief Executive Officer & Board Member 000 0000
You’re viewing 5 of 19 board members. Get the full list »

Orchard Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Orchard Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Orchard Therapeutics‘s full profile, request access.

Request a free trial

Orchard Therapeutics Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000000000 (0 12-Apr-2018 000000000 00000 00 Buildings and Property 0000 0000000
To view Orchard Therapeutics’s complete investments history, request access »